Black Bird Biotech, Inc.
BBBT · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -1.68% | -7.81% | -57.16% | -49.03% |
| EV / EBITDA | 24.79 | -9.79 | -10.85 | -6.85 |
| Quality | ||||
| ROIC | 6.23% | -471.21% | 1,124.50% | -645.25% |
| Gross Margin | 36.02% | 54.10% | 45.85% | 12.52% |
| Cash Conversion Ratio | 0.04 | 0.08 | 0.37 | 0.47 |
| Growth | ||||
| Revenue 3-Year CAGR | -24.20% | 0.69% | 12.20% | 12.75% |
| Free Cash Flow Growth | 67.06% | 84.98% | 13.31% | 8.31% |
| Safety | ||||
| Net Debt / EBITDA | 17.80 | -7.75 | -8.72 | -4.99 |
| Interest Coverage | -0.09 | -0.92 | -0.45 | -1.10 |
| Efficiency | ||||
| Inventory Turnover | 0.03 | 0.08 | 0.05 | 0.12 |
| Cash Conversion Cycle | 368.24 | 284.95 | 576.34 | -114.91 |